CLDX Valuation

Celldex Therapeutics Inc

Add to Watchlist

Advanced Chart

22.020

+1.13(5.409%)1D

Overview
Forecast
Valuation
Earnings

CLDX Relative Valuation

CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLDX is overvalued; if below, it's undervalued.

Historical Valuation

Celldex Therapeutics Inc (CLDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -13.63. The fair price of Celldex Therapeutics Inc (CLDX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 20.89 USD , Celldex Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：20.89

Fair

Undervalued

-5.38

Trailing

Forward

-3.55

EV/EBITDA

Celldex Therapeutics Inc. (CLDX) has a current EV/EBITDA of -3.55. The 5-year average EV/EBITDA is -2.10. The thresholds are as follows: Strongly Undervalued below -9.44, Undervalued between -9.44 and -5.77, Fairly Valued between 1.57 and -5.77, Overvalued between 1.57 and 5.24, and Strongly Overvalued above 5.24. The current Forward EV/EBITDA of -3.55 falls within the Historic Trend Line -Fairly Valued range.

-3.51

EV/EBIT

Celldex Therapeutics Inc. (CLDX) has a current EV/EBIT of -3.51. The 5-year average EV/EBIT is -9.98. The thresholds are as follows: Strongly Undervalued below -21.75, Undervalued between -21.75 and -15.87, Fairly Valued between -4.10 and -15.87, Overvalued between -4.10 and 1.79, and Strongly Overvalued above 1.79. The current Forward EV/EBIT of -3.51 falls within the Overvalued range.

355.86

Celldex Therapeutics Inc. (CLDX) has a current PS of 355.86. The 5-year average PS is 555.29. The thresholds are as follows: Strongly Undervalued below -24.09, Undervalued between -24.09 and 265.60, Fairly Valued between 844.98 and 265.60, Overvalued between 844.98 and 1134.68, and Strongly Overvalued above 1134.68. The current Forward PS of 355.86 falls within the Historic Trend Line -Fairly Valued range.

-7.76

P/OCF

Celldex Therapeutics Inc. (CLDX) has a current P/OCF of -7.76. The 5-year average P/OCF is -11.22. The thresholds are as follows: Strongly Undervalued below -31.25, Undervalued between -31.25 and -21.24, Fairly Valued between -1.20 and -21.24, Overvalued between -1.20 and 8.82, and Strongly Overvalued above 8.82. The current Forward P/OCF of -7.76 falls within the Historic Trend Line -Fairly Valued range.

-7.80

P/FCF

Celldex Therapeutics Inc. (CLDX) has a current P/FCF of -7.80. The 5-year average P/FCF is -14.18. The thresholds are as follows: Strongly Undervalued below -31.13, Undervalued between -31.13 and -22.65, Fairly Valued between -5.70 and -22.65, Overvalued between -5.70 and 2.77, and Strongly Overvalued above 2.77. The current Forward P/FCF of -7.80 falls within the Historic Trend Line -Fairly Valued range.

Celldex Therapeutics Inc (CLDX) has a current Price-to-Book (P/B) ratio of 2.18. Compared to its 3-year average P/B ratio of 4.00 , the current P/B ratio is approximately -45.48% higher. Relative to its 5-year average P/B ratio of 4.30, the current P/B ratio is about -49.33% higher. Celldex Therapeutics Inc (CLDX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -7.34%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.29% , the current FCF yield is about -100.00% lower.

2.12

P/B

Median3y

4.00

Median5y

4.30

-11.82

FCF Yield

Median3y

-7.34

Median5y

-6.29

Competitors Valuation Multiple

The average P/S ratio for CLDX's competitors is 73.25, providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of 355.86, which is 385.80% above the industry average. Given its robust revenue growth of -70.78%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLDX.O

Celldex Therapeutics Inc

Twist Bioscience Corp

Cogent Biosciences Inc

Loss

1.64B

IMCR.O

Immunocore Holdings PLC

BioCryst Pharmaceuticals Inc

2.70

49.41%

1.76B

Performance Decomposition

Market capitalization of CLDX decreased by 46.72% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.43K to -7.75K.

The secondary factor is the Revenue Growth, contributed -70.78%to the performance.

Overall, the performance of CLDX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-70.78%

2.50M → 730.00K

Revenue Growth

440.37%

-1.43K → -7.75K

Margin Expansion

-416.31%

2.20 → -6.95

P/E Change

-46.72%